{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:00:30Z","timestamp":1790359230484,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biotest AG"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    The 10% intravenous immunoglobulin (IVIG) BT595 was evaluated in an open-label, prospective, multicenter clinical trial (Trial 991; NCT02810444) to characterize IgG subclass pharmacokinetics as replacement therapy in patients with primary immunodeficiency (PID). Patients received BT595 at either a 3-week (Q3W) or 4-week (Q4W) dosing interval for approximately 12 months. Secondary endpoints included steady state trough concentrations and pharmacokinetic parameters of IgG subclasses 1\u20134 and total IgG. IgG subclass trough concentrations were assessed at baseline and at steady state prior to the 7th infusion (Q3W) or 5th infusion (Q4W). Pharmacokinetic parameters at steady state were determined in patients aged \u22656 years using serum samples collected predose and up to 28 days post infusion. At steady state, trough concentrations of total IgG and all IgG subclasses were comparable between BT595 and patients\u2019 previous IVIG therapy, indicating preservation of systemic IgG exposure following treatment switch. IgG subclass trough concentrations were stable across dosing regimens and age categories, with a proportional distribution closely matching physiological IgG composition. IgG1 and IgG2 accounted for the majority of total IgG, whereas IgG3 and IgG4 contributed smaller fractions, consistent with endogenous IgG and published IVIG data. Pharmacokinetic profiles of all IgG subclasses were consistent with those reported for licensed IVIG products. Maximum concentrations occurred rapidly after infusion, and systemic exposure was robust under both dosing regimens. Mean concentrations and C\n                    <jats:sub>max<\/jats:sub>\n                    values were higher with Q3W dosing, while exposure over the dosing interval (AUC\n                    <jats:sub>tau<\/jats:sub>\n                    ) was lower compared with Q4W dosing due to the shorter interval. Estimated half-life values were within or above ranges reported for other IVIG products, with numerically prolonged persistence of IgG2 and IgG4 under Q4W dosing. Overall, BT595 provides sustained IgG subclass exposure at steady state, supporting its suitability as IVIG replacement therapy in PID under both Q3W and Q4W regimens.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0357472","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:08Z","timestamp":1790357348000},"page":"e0357472","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levels of IgG subclasses 1\u20134 in BT595, a 10% IVIG: A sub-analysis of a clinical trial"],"prefix":"10.1371","volume":"21","author":[{"given":"Fabian","family":"Bohl\u00e4nder","sequence":"first","affiliation":[{"name":"Biotest AG","place":["Dreieich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Aigner","sequence":"additional","affiliation":[{"name":"Biotest AG","place":["Dreieich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sch\u00fctze","sequence":"additional","affiliation":[{"name":"Biotest AG","place":["Dreieich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Sch\u00fcttrumpf","sequence":"additional","affiliation":[{"name":"Biotest AG","place":["Dreieich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-7687","authenticated-orcid":true,"given":"Christiane","family":"Staiger","sequence":"additional","affiliation":[{"name":"Biotest AG","place":["Dreieich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"3","key":"pone.0357472.ref001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40268-023-00430-w","article-title":"Biochemical characterization of a new 10% IVIG preparation [IgG next generation (BT595)\/Yimmugo\u00ae] obtained from a manufacturing process preserving IgA\/IgM potential of human plasma","volume":"23","author":"C Duellberg","year":"2023","journal-title":"Drugs R D"},{"issue":"10","key":"pone.0357472.ref002","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/vox.13337","article-title":"Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease","volume":"117","author":"G Kriv\u00e1n","year":"2022","journal-title":"Vox Sang"},{"issue":"3","key":"pone.0357472.ref003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10875-022-01397-0","article-title":"BT595, a 10% human normal immunoglobulin, for replacement therapy of primary immunodeficiency disease: results of a subcohort analysis in children","volume":"43","author":"G Kriv\u00e1n","year":"2023","journal-title":"J Clin Immunol"},{"key":"pone.0357472.ref004","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"G Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"pone.0357472.ref005","doi-asserted-by":"crossref","first-page":"1304365","DOI":"10.3389\/fimmu.2023.1304365","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"T Damelang","year":"2024","journal-title":"Front Immunol"},{"key":"pone.0357472.ref006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molimm.2015.03.255","article-title":"Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases","volume":"67","author":"V Irani","year":"2015","journal-title":"Mol Immunol"},{"issue":"11","key":"pone.0357472.ref007","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"T Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"pone.0357472.ref008","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/cells14090639","article-title":"Role of IgG4 antibodies in human health and disease","volume":"14","author":"L-L Shi","year":"2025","journal-title":"Cells"},{"issue":"4","key":"pone.0357472.ref009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/08820139.2020.1775643","article-title":"Immunological role of IgG subclasses","volume":"50","author":"C Napodano","year":"2021","journal-title":"Immunol Invest"},{"issue":"9","key":"pone.0357472.ref010","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"DC Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"pone.0357472.ref011","first-page":"13","article-title":"IgG subclass deficiency","volume":"3","author":"RM Petrak","year":"2023","journal-title":"Priv Pract Infect Dis"},{"key":"pone.0357472.ref012","author":"European Medicines Agency","year":"2015"},{"key":"pone.0357472.ref013","author":"Food and Drug Administration (FDA).","year":"2001"},{"key":"pone.0357472.ref014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13223-017-0216-7","article-title":"Adult reference intervals for IgG subclasses with Siemens immunonephelometric assays in Chinese population","volume":"13","author":"P Li","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"pone.0357472.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"JS Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0357472.ref016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","article-title":"Intravenous immunoglobulin: an update on the clinical use and mechanisms of action","volume":"27","author":"VS Negi","year":"2007","journal-title":"J Clin Immunol"},{"key":"pone.0357472.ref017","author":"European Medicines Agency","year":"2021"},{"key":"pone.0357472.ref018","author":"Food and Drug Administration","year":"2008"},{"issue":"5","key":"pone.0357472.ref019","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"S Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"issue":"3","key":"pone.0357472.ref020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1423-0410.2003.00278.x","article-title":"Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes","volume":"84","author":"M-A Alyanakian","year":"2003","journal-title":"Vox Sang"},{"issue":"4","key":"pone.0357472.ref021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"M Berger","year":"2004","journal-title":"J Clin Immunol"},{"issue":"4","key":"pone.0357472.ref022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1423-0410.2006.00764.x","article-title":"Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia","volume":"90","author":"J Bj\u00f6rkander","year":"2006","journal-title":"Vox Sang"},{"key":"pone.0357472.ref023","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","article-title":"Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency","volume":"37","author":"RL Wasserman","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"pone.0357472.ref024","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/cpt.693","article-title":"Pharmacokinetics and pharmacodynamics of intravenous immunoglobulin G maintenance therapy in chronic immune-mediated neuropathies","volume":"102","author":"W Fokkink","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0357472.ref025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejps.2018.03.007","article-title":"Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: analysis of a phase III, multicentre, prospective, open-label study","volume":"118","author":"IR Melamed","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"pone.0357472.ref026","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2500\/aap.2024.45.240033","article-title":"Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin","volume":"45","author":"M Paddick","year":"2024","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"pone.0357472.ref027","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"FA Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"pone.0357472.ref028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10875-017-0416-4","article-title":"A multicentre study on the efficacy, safety and pharmacokinetics of IqYmune\u00ae, a highly purified 10% liquid intravenous immunoglobulin, in patients with primary immune deficiency","volume":"37","author":"G Krivan","year":"2017","journal-title":"J Clin Immunol"},{"issue":"3","key":"pone.0357472.ref029","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/vox.12275","article-title":"An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease","volume":"109","author":"G Kriv\u00e1n","year":"2015","journal-title":"Vox Sang"},{"issue":"4","key":"pone.0357472.ref030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","article-title":"Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency","volume":"32","author":"RL Wasserman","year":"2012","journal-title":"J Clin Immunol"},{"issue":"6","key":"pone.0357472.ref031","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s10875-016-0308-z","article-title":"Efficacy, Safety, and Pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease","volume":"36","author":"RL Wasserman","year":"2016","journal-title":"J Clin Immunol"},{"issue":"5","key":"pone.0357472.ref032","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10875-020-00788-5","article-title":"A systematic review and meta-regression analysis on the impact of increasing igg trough level on infection rates in primary immunodeficiency patients on intravenous IgG therapy","volume":"40","author":"JL Lee","year":"2020","journal-title":"J Clin Immunol"},{"issue":"13","key":"pone.0357472.ref033","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/1750743X.2024.2382074","article-title":"Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies","volume":"16","author":"Z Li","year":"2024","journal-title":"Immunotherapy"},{"key":"pone.0357472.ref034","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antib9020024","article-title":"Considerations for optimizing dosing of immunoglobulins based on pharmacokinetic evidence","volume":"9","author":"I Mahmood","year":"2020","journal-title":"Antibodies"},{"issue":"4","key":"pone.0357472.ref035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4168\/aair.2021.13.4.671","article-title":"Establishment of reference intervals of serum immunoglobulins in healthy Korean adults","volume":"13","author":"JH Jang","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"issue":"3","key":"pone.0357472.ref036","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF01958271","article-title":"Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile charts","volume":"149","author":"A Plebani","year":"1989","journal-title":"Eur J Pediatr"},{"issue":"6","key":"pone.0357472.ref037","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: a systematic review","volume":"26","author":"T Koleba","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"3","key":"pone.0357472.ref038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00918706","article-title":"Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency","volume":"6","author":"RI Schiff","year":"1986","journal-title":"J Clin Immunol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:13Z","timestamp":1790357353000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357472"}},"subtitle":[],"editor":[{"given":"Shahina","family":"Akter","sequence":"first","affiliation":[{"name":"Bangladesh Council of Scientific and Industrial Research","place":["BANGLADESH"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357472","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}